Esreboxetine is under clinical development by Axsome Therapeutics and currently in Phase III for Fibromyalgia (Fibromyalgia Syndrome). According to GlobalData, Phase III drugs for Fibromyalgia (Fibromyalgia Syndrome) have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Esreboxetine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SS-RBX (S,S-Reboxetine, esreboxetine) is under development for the treatment of fibromyalgia. S,S-Reboxetine is administered through oral route. The drug candidate acts by targeting sodium dependent noradrenaline transporter.
It was also under development for the treatment of chronic painful diabetic peripheral neuropathy, postherpetic neuralgia, and stress urinary incontinence.
Axsome Therapeutics overview
Axsome Therapeutics (Axsome) is a biopharmaceutical company that develops and commercializes therapies for the treatment of central nervous system (CNS) disorders. The company’s pipeline product portfolio comprises AXS-05, for treatment of resistant depression, smoking cessation and agitation in Alzheimer’s disease, AXS-07, for treatment of migraine, AXS-12, for symptoms of narcolepsy, and AXS-14, for treatment of fibromyalgia. The company supplies its products through internal sales, distributors, and an internal marketing group in the US and outside the US. Axsome is headquartered in New York, the US.
For a complete picture of Esreboxetine’s drug-specific PTSR and LoA scores, buy the report here.